Bayer Schering Pharma announced the upcoming launch in China of Betaferon® (interferon beta-1b) for the treatment of relapsing-remitting forms of multiple sclerosis (MS).
Betaferon is already approved in over 100 countries worldwide.
With Betaferon and Gadovist®1.0, which was also recently launched in China, Bayer Healthcare China aims to provide Chinese multiple sclerosis patients with a comprehensive range of services from diagnosis to therapy. Gadovist 1.0, a contrast agent for use in magnetic resonance imaging (MRI), has been approved in China for the diagnosis of diseases affecting the central nervous system, including MS, and for blood-vessel imaging....Read More -
http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1902
Login
Register
FAQ
Search
